FR16C0031I2 - S-TRIAZOLYL ALPHA-MERCAPTOACETANILIDES AS HIV REVERSE TRANSCRIPTASE INHIBITORS - Google Patents

S-TRIAZOLYL ALPHA-MERCAPTOACETANILIDES AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Info

Publication number
FR16C0031I2
FR16C0031I2 FR16C0031C FR16C0031C FR16C0031I2 FR 16C0031 I2 FR16C0031 I2 FR 16C0031I2 FR 16C0031 C FR16C0031 C FR 16C0031C FR 16C0031 C FR16C0031 C FR 16C0031C FR 16C0031 I2 FR16C0031 I2 FR 16C0031I2
Authority
FR
France
Prior art keywords
mercaptoacetanilides
reverse transcriptase
transcriptase inhibitors
hiv reverse
triazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0031C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of FR16C0031I1 publication Critical patent/FR16C0031I1/fr
Application granted granted Critical
Publication of FR16C0031I2 publication Critical patent/FR16C0031I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A series of S-triazolyl ±-mercaptoacetanilides having general structure (I) are provided, where Q is CO 2 H, CONR 2 , SO 3 H,or SO 2 NR 2 . The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
FR16C0031C 2004-08-25 2016-07-29 S-TRIAZOLYL ALPHA-MERCAPTOACETANILIDES AS HIV REVERSE TRANSCRIPTASE INHIBITORS Active FR16C0031I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60422004P 2004-08-25 2004-08-25
US60421904P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
EP05790722A EP1789039B1 (en) 2004-08-25 2005-08-25 S-triazolyl alpha -mercaptoacetanildes as inhibitors of hiv reverse transcriptase

Publications (2)

Publication Number Publication Date
FR16C0031I1 FR16C0031I1 (en) 2016-09-23
FR16C0031I2 true FR16C0031I2 (en) 2017-03-31

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0031C Active FR16C0031I2 (en) 2004-08-25 2016-07-29 S-TRIAZOLYL ALPHA-MERCAPTOACETANILIDES AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Country Status (32)

Country Link
US (8) US7947721B2 (en)
EP (5) EP2433633A1 (en)
JP (2) JP4952943B2 (en)
KR (1) KR101241716B1 (en)
CN (2) CN101817793B (en)
AT (2) ATE540677T1 (en)
AU (2) AU2005280130C9 (en)
BR (2) BRPI0514630B8 (en)
CA (1) CA2578068C (en)
CY (2) CY1112221T1 (en)
DK (1) DK2135608T3 (en)
EA (2) EA014737B1 (en)
EC (1) ECSP077322A (en)
ES (2) ES2380604T3 (en)
FR (1) FR16C0031I2 (en)
HK (1) HK1133582A1 (en)
HR (1) HRP20130075T1 (en)
HU (1) HUS1600034I1 (en)
IL (3) IL181523A (en)
IN (1) IN2014CN03762A (en)
LT (1) LTC2135608I2 (en)
LU (1) LU93169I2 (en)
ME (1) ME01512B (en)
MX (1) MX2007002236A (en)
NL (1) NL300825I2 (en)
NZ (2) NZ581376A (en)
PL (1) PL2135608T3 (en)
PT (1) PT2135608E (en)
RS (1) RS52632B (en)
SG (2) SG155246A1 (en)
SI (1) SI2135608T1 (en)
WO (1) WO2006026356A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2433633A1 (en) * 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
MX2009012704A (en) 2007-05-30 2009-12-08 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors.
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
CN103058944B (en) * 2007-11-27 2015-08-05 亚德生化公司 Regulate the compound of blood uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
BRPI0918586A2 (en) * 2008-09-04 2015-12-01 Ardea Biosciences Inc compounds, compositions and methods of use thereof for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2349258A1 (en) * 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (en) * 2009-10-10 2014-10-15 台州市华南医化有限公司 Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide
JP5696346B2 (en) * 2010-01-08 2015-04-08 アルデア バイオサイエンシーズ インク． Polymorphism, crystallinity, and mesophase of sodium 2- (5-bromo-4- (4-cyclopropylnaphthalen-1-yl) -4H-1,2,4-triazol-3-ylthio) acetate Form and its use
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
SI2582683T1 (en) 2010-06-15 2018-07-31 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
AR081930A1 (en) 2010-06-16 2012-10-31 Ardea Biosciences Inc THIOACETATE COMPOUNDS
TWI499412B (en) 2010-06-16 2015-09-11 Ardea Biosciences Inc Phenylthioacetate compositions and methods of use
CN101899013B (en) * 2010-07-12 2012-07-25 山东大学 2-(2-substituted aryl-2H-1,2,4-triazole-3-sulfydryl) acetamide derivative and preparation method and application thereof
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
KR101541629B1 (en) 2010-12-30 2015-08-03 아디아 바이오사이언스즈 인크. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
DK2776028T3 (en) 2011-11-03 2019-02-04 Ardea Biosciences Inc 3,4-DISUBSTITUTED PYRIDIDE COMPOUND, PROCEDURES FOR USING IT AND COMPOSITIONS INCLUDING THIS
AR091651A1 (en) * 2012-07-03 2015-02-18 Ardea Biosciences Inc ACID ELABORATION 2- (5-BROMO-4- (4-CICLOPROPILNAFTALEN-1-IL) -4H-1,2,4-TRIAZOL-3-ILTIO) ACETIC
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (en) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 The preparation method of gout therapertics Lesinurad and Lesinurad intermediate
EP3071554B1 (en) * 2013-11-22 2018-10-03 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad
CN104557748A (en) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 Novel solid form of sulpho-1,2,4-triazole derivative
CN105315218A (en) * 2014-07-17 2016-02-10 天津药物研究院 Preparation method of lesinurad intermediate namely 1-naphthyltriazole thioketone
CN104370841B (en) * 2014-10-27 2016-07-13 张远强 Triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104327000B (en) * 2014-10-27 2016-08-17 张远强 Phenyl substituted triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104341363B (en) * 2014-10-27 2016-08-17 张远强 A kind of nitro substituted triazole sulphonyl malonic acid compounds, Preparation Method And The Use
CN104341361B (en) * 2014-10-27 2017-01-11 张远强 Cyano-substituted triazolesulfonylmalonic acid compounds as well as preparation method and application thereof
CN104370842B (en) * 2014-10-27 2016-07-13 张远强 The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use
CN104326998B (en) * 2014-10-27 2016-08-17 张远强 Phenyl substituted triazole malonic acid compounds, Preparation Method And The Use
CN104341362B (en) * 2014-10-27 2016-07-13 张远强 Triazole sulphonyl malonic acid compounds, Preparation Method And The Use
CN104326993B (en) * 2014-10-27 2016-08-17 张远强 A kind of nitro substituted 1,2,4-triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104311498B (en) * 2014-10-27 2016-04-06 张远强 Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (en) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 Preparing method for (4-(4-cyclopropyl-naphthalene-1-yl)-5-nitr-4H-(1, 2, 4) triazole-3-ylsulfanyl)-ethyl acetate and intermediate (5-nitr-4H-(1, 2, 4) triazole-3-sulfenyl)-ethyl acetate thereof
CN105153056A (en) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylthioalkyl]-methyl acetate
CN105017168A (en) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (en) * 2016-03-01 2018-05-18 山东大学 A kind of preparation method for the triazole mercapto phenylacetic acid compound for treating gout
DK3473617T3 (en) 2016-06-17 2022-11-28 Medshine Discovery Inc HALOGENATED COMPOUND AND AXIAL, CHIRAL ISOMERS THEREOF
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (en) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 Novel preparation method of anti-gout drug Lesinurad and key intermediate thereof
WO2019001325A1 (en) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 Crystal form xv of lesinurad and preparation method therefor
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
DE112022002825T5 (en) 2021-05-28 2024-03-14 Sumitomo Chemical Company, Limited Process for the preparation of cycloalkyl bromide

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226186A (en) 1880-04-06 Car-coupling
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
JPS5641637B2 (en) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (en) 1994-01-27 1995-08-15 Torii Yakuhin Kk Compound having antiviral activity
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
EP0910565A1 (en) 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
JPH10243033A (en) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd Demodulator
DE69943247D1 (en) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV-inhibiting pyrimidine derivatives
IL143105A0 (en) 1998-11-12 2002-04-21 Neurocrine Biosciences Inc Fused polycyclic heterocyclic compounds and pharmaceutical compositions containing the same
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
NZ512184A (en) * 1998-12-25 2003-08-29 Shionogi & Co Aromatic heterocycle compounds having HIV integrase inhibiting activities
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
NZ527864A (en) 2001-03-02 2004-05-28 Smithkline Beecham Corp Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
WO2003097047A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
EA009478B1 (en) * 2002-08-23 2008-02-28 Ардеа Байосайенсиз, Инк. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
KR20110132482A (en) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Pyrimidine derivatives for the prevention of hiv infection
WO2005028479A2 (en) 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
CN103058944B (en) * 2007-11-27 2015-08-05 亚德生化公司 Regulate the compound of blood uric acid levels
EP2349258A1 (en) 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
CN101817793B (en) 2014-01-08
ATE540677T1 (en) 2012-01-15
KR20070054694A (en) 2007-05-29
ECSP077322A (en) 2007-04-26
BRPI0514630B1 (en) 2020-09-15
HUS1600034I1 (en) 2016-09-28
ES2374773T3 (en) 2012-02-21
WO2006026356A2 (en) 2006-03-09
US20080176850A1 (en) 2008-07-24
BRPI0514630B8 (en) 2021-05-25
EP2135608A1 (en) 2009-12-23
IL201546A (en) 2013-10-31
CY2016028I2 (en) 2016-12-14
CY1112221T1 (en) 2015-12-09
EP1789039A4 (en) 2009-08-05
AU2009217458B2 (en) 2009-11-19
US8003681B2 (en) 2011-08-23
MX2007002236A (en) 2007-07-09
ES2380604T3 (en) 2012-05-16
AU2009217458A1 (en) 2009-10-15
LTPA2016024I1 (en) 2016-09-12
LU93169I2 (en) 2016-10-10
EP2609917A1 (en) 2013-07-03
NL300825I2 (en) 2017-01-24
HK1133582A1 (en) 2010-04-01
AU2005280130B2 (en) 2009-09-10
BRPI0520870B1 (en) 2020-11-10
CY2016028I1 (en) 2016-12-14
FR16C0031I1 (en) 2016-09-23
US20110190491A1 (en) 2011-08-04
EA200901186A1 (en) 2010-04-30
SG185992A1 (en) 2012-12-28
CA2578068A1 (en) 2006-03-09
CN101083987B (en) 2011-01-26
SI2135608T1 (en) 2012-03-30
US8946273B2 (en) 2015-02-03
AU2005280130C1 (en) 2010-02-18
US20150094284A1 (en) 2015-04-02
IL181523A0 (en) 2007-07-04
BRPI0520870B8 (en) 2021-05-25
PL2135608T3 (en) 2012-07-31
EA014737B1 (en) 2011-02-28
SG155246A1 (en) 2009-09-30
US20180002296A1 (en) 2018-01-04
WO2006026356A3 (en) 2006-08-10
DK2135608T3 (en) 2012-01-23
US7947721B2 (en) 2011-05-24
EP2402011A1 (en) 2012-01-04
AU2005280130A1 (en) 2006-03-09
LTC2135608I2 (en) 2017-07-25
EP2135608B8 (en) 2012-03-21
AU2005280130C9 (en) 2010-03-04
EP1789039A2 (en) 2007-05-30
BRPI0514630A (en) 2008-06-17
US8252828B2 (en) 2012-08-28
IL181523A (en) 2013-12-31
CA2578068C (en) 2011-08-09
EA015846B1 (en) 2011-12-30
CN101817793A (en) 2010-09-01
KR101241716B1 (en) 2013-03-08
NZ581376A (en) 2011-05-27
JP5457472B2 (en) 2014-04-02
US20100081827A1 (en) 2010-04-01
CN101083987A (en) 2007-12-05
EP2433633A1 (en) 2012-03-28
JP2012077088A (en) 2012-04-19
US20110313157A1 (en) 2011-12-22
NZ553534A (en) 2010-10-29
EA200700488A1 (en) 2007-08-31
JP4952943B2 (en) 2012-06-13
IN2014CN03762A (en) 2015-09-25
JP2008510828A (en) 2008-04-10
ATE528001T1 (en) 2011-10-15
EP1789039B1 (en) 2012-01-11
PT2135608E (en) 2012-01-13
US20100267724A2 (en) 2010-10-21
US8481581B2 (en) 2013-07-09
HRP20130075T1 (en) 2013-02-28
IL219131A0 (en) 2012-06-28
ME01512B (en) 2014-04-20
US20120283301A1 (en) 2012-11-08
US20100069645A1 (en) 2010-03-18
AU2009217458A8 (en) 2009-10-29
EP2402011B1 (en) 2012-11-14
RS52632B (en) 2013-06-28
EP2135608B1 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
FR16C0031I2 (en) S-TRIAZOLYL ALPHA-MERCAPTOACETANILIDES AS HIV REVERSE TRANSCRIPTASE INHIBITORS
BR0309557A (en) Non-Nucleoside Reverse Transcriptase Inhibitors
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
ATE494893T1 (en) SULFONAMIDES, SULFAMATES AND SULFAMIDES AS GAMMA SECRETASE INHIBITORS
NO20071871L (en) Phosphoindoles as HIV inhibitors.
NO20064547L (en) Methods for treating HIV infection
DE60237725D1 (en) DEVICE OF DEXRAZOXANE IN THE PREVENTION AND TREATMENT OF ALZHEIMER DISEASE
ATE373005T1 (en) THIENOPYRROLES AS ANTIVIRAL AGENTS
NO20073765L (en) Compounds for the treatment of flaviviridae
DE60221508D1 (en) Amino acid derivatives as HIV protease inhibitors
UY29012A1 (en) "OXAZOLIDIDONS AND RELATED COMPOSITIONS AND METHODS"
BRPI0409586A (en) hydroxamic acids useful in treating hyperproliferative disorders
UA89200C2 (en) S-TRIAZOLYL-α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
RU2003100730A (en) METHOD FOR PLASTIC CARE BIFURCATION PLASTIC